Related Experiment Video

Updated: Jun 4, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Oridonin: An active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer

Chun-yang Li1, En-qin Wang, Yan Cheng

  • 1School of Life Sciences & State Key Laboratory of Oral Diseases, Sichuan University, Chengdu 610064, China.

The International Journal of Biochemistry & Cell Biology
|February 8, 2011
PubMed

Insights

Oridonin, a natural compound, effectively halts cancer cell proliferation by inducing cell cycle arrest and apoptosis. Its molecular mechanisms offer potential for new anti-cancer drug development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cell cycle arrest and cell death are critical in tumor progression.
  • Understanding these processes is vital for cancer biology.
  • Oridonin is a diterpenoid with known anti-proliferative effects.

Purpose of the Study:

  • To review recent research on oridonin's anti-cancer properties.
  • To explore oridonin's molecular mechanisms in cancer cells.
  • To evaluate oridonin as a potential anti-neoplastic therapeutic.

Main Methods:

  • Literature review of studies on oridonin.
  • Analysis of molecular pathways involved in cell cycle arrest, apoptosis, and autophagy.
  • Examination of cross-talk between these pathways.

Main Results:

  • Oridonin exhibits significant anti-proliferative activity.
  • Molecular mechanisms include induction of cell cycle arrest and apoptosis.
  • Autophagy and its interplay with other pathways are influenced by oridonin.

Conclusions:

  • Oridonin demonstrates potent anti-cancer effects through multiple molecular pathways.
  • Its ability to induce cell cycle arrest and apoptosis is a key finding.
  • Oridonin shows promise as a candidate for future cancer therapeutics.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...